Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
With an estimated total addressable market of $200 million annually [1], Nu.Q® Discover targets a smaller market than our other larger pillars, but it is proving to be a strong source of early revenue and is validating the wide applicability and utility of our Nu.Q® platform with some of the world's biggest healthcare companies. With a powerful portfolio of 14 state-of-the-art immunoassays, Nu.Q® Discover is now serving over 20 clients worldwide, accelerating disease research and drug development across multiple therapeutic areas. Built on Volition's proprietary nucleosome quantification technology, Nu.Q® Discover offers unparalleled insight through high-throughput epigenetic profiling as a service to large Pharma and diagnostic companies for their own development programs. The Nu.Q® platform's versatility across biological samples and disease models was recently validated in a peer-reviewed publication in the Journal of Biological Chemistry titled: "High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development." Volition is committed to expanding the Nu.Q® Discover offering and delivering significant value to the life sciences community. The company anticipates continued growth in 2025, including multiple new contracts, building on the strong foundation of scientific excellence and global commercial traction established to date.
Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition said:
"We've seen strong and growing demand for Nu.Q® assays as exploratory biomarkers in 3rd parties' multi-national clinical trials, with multiple global clients placing repeat orders. The largest of these projects has projected revenue in the hundreds of thousands of dollars, for an ongoing longitudinal Phase 1/2b study targeting completion in 2026.
"Our robust pipeline and ongoing service expansion suggests continued strong Nu.Q® Discover revenue growth this year.
"Pharma companies are using Nu.Q® assays as exploratory biomarkers today — and if/when they advance to companion diagnostic use, this could translate into high-value, multi-million dollar, long-term partnerships.
"We're also actively exploring co-marketing partnerships to meet the demand for Nu.Q® Discover we are seeing worldwide and hope to be able to sign such a deal in the coming months."
About Nu.Q® Discover
Nu.Q® Discover empowers pharmaceutical and biotech developers with rapid high-throughput epigenetic profiling across key biological processes. The platform supports the entire drug development continuum—from preclinical studies to clinical validation—with biomarkers designed to:
Assess disease severity
Monitor treatment response
Deepen understanding of disease mechanisms
Its applications span oncology, neurodegenerative and autoimmune diseases and NETosis—making it one of the most versatile epigenetic solutions on the market today.To learn more about Nu.Q® Discover or to request a collaboration, visit https://volition.com/nu-q-discover-work-with-us/#working-with-us.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the total addressable market for Nu.Q® Discover, , Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing, distribution and/or other agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
[1] Data on file, Volition Total Addressable Market Model
Photo: https://mma.prnewswire.com/media/2732448/VolitionRxLimited_Assays.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuq-discover-expands-global-adoption-and-epigenetic-innovation-302506707.html
SOURCE VolitionRx Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
CrowdStrike Named a Leader in the 2025 Gartner® Magic Quadrant™ for Endpoint Protection Platforms for Sixth Consecutive Time
AUSTIN, Texas--(BUSINESS WIRE)-- CrowdStrike (NASDAQ: CRWD) today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Endpoint Protection Platforms (EPP) 1 for the sixth consecutive time. For the third time in a row, CrowdStrike was positioned furthest right for Completeness of Vision and highest for Ability to Execute among all vendors evaluated. The AI-native CrowdStrike Falcon® platform continues to define endpoint protection for the AI era, delivering industry-leading prevention, detection, and response. CrowdStrike's single-agent platform architecture meets growing customer demand to consolidate cybersecurity, unifying best-in-class endpoint, identity, cloud, data protection, and next-gen SIEM. With breakthrough agentic AI innovations, Falcon automates decisions and completes tasks to supercharge SOC personnel and accelerate security outcomes. 'As the pioneer of AI-native endpoint protection, CrowdStrike continues to lead the industry in delivering the outcome that matters most: stopping breaches,' said Elia Zaitsev, chief technology officer, CrowdStrike. 'The Falcon platform's unified architecture drives relentless innovation across the modern attack surface – consolidating point products, closing protection gaps, and simplifying operations. By wiring AI-driven automation into security workflows, Falcon autonomously makes critical decisions and drives real-time action, delivering the next evolution of AI-powered security operations. We believe this recognition validates Falcon as the platform of choice for modern cybersecurity.' Cybersecurity's Platform Innovator for the AI Era CrowdStrike continues to innovate its endpoint and platform capabilities to keep customers ahead of evolving threats and transform security operations. The company recently unveiled File System Containment for endpoint, which prevents ransomware from spreading over the network via Windows Server Message Block (SMB) and stops mass encryption as early as possible. Agentic AI innovations – including Charlotte AI Agentic Detection Triage and Charlotte AI Agentic Response and Agentic Workflows – transcend 'ask-and-respond' co-pilots, delivering autonomous reasoning and action on first- and third-party data, without human prompts. Advancements in Falcon Cloud Security protect every layer of cloud risk – from AI models to runtime data. Falcon Data Protection innovations unify data security across endpoints, cloud, GenAI, and SaaS. Falcon Identity Protection now secures the entire identity attack lifecycle – from initial access to privilege escalation and lateral movement – across hybrid environments. With every module managed from a single console, Falcon delivers AI-driven protection – trained on trillions of daily events and frontline intelligence – across the entire platform, without relying on stitched-together data or disconnected systems. 2 In May 2025, CrowdStrike was named a Customers' Choice in the 2025 Gartner Peer Insights™ 'Voice of the Customer' for Endpoint Protection Platforms report, with the most 5-star ratings (450) of any Customers' Choice vendor. To learn more about CrowdStrike's recognition in the 2025 Gartner® Magic Quadrant™ for Endpoint Protection Platforms (EPP), please visit our website and read our blog. 1. Gartner, 2025 Gartner® Magic Quadrant™ for Endpoint Protection Platforms (EPP), Evgeny Mirolyubov, Franz Hinner, Deepak Mishra, July 14, 2025 2. Gartner, Voice of the Customer for Endpoint Protection Platforms, Peer Editors, May 23, 2025 GARTNER is a registered trademark and service mark, Magic Quadrant and PEER INSIGHTS are a registered trademark, of Gartner Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.
Business Wire
13 minutes ago
- Business Wire
PCI ® Secures HITRUST Recertification–Again
WESTON, Fla.--(BUSINESS WIRE)--Postal Center International® (PCI®), one of the nation's leading providers of mail, print, fulfillment, signs, and marketing solutions, today announced it has earned recertification for the HITRUST Risk-based, 2-year (r2) Certification – a highly esteemed benchmark that validates the strength of PCI's information security and risk management programs. "In an era where security is synonymous with client confidence, this certification reinforces PCI's reputation as a technology-forward, compliance-first organization that leads with integrity, accountability, and innovation." Share This elite achievement places PCI among a select group of global organizations recognized for their ability to safeguard sensitive information through rigorous compliance with key industry standards and regulations. The HITRUST r2 Certification confirms that PCI's IT infrastructure, systems, and workflow processes meet comprehensive security requirements derived from a wide range of federal and state regulations, frameworks, and risk-based controls. 'Achieving HITRUST r2 recertification is a badge of honor and is proof of our relentless commitment to safeguarding the trust our clients place in us every day,' said Ismael Diaz, President & CEO of PCI. 'In an era where security is synonymous with client confidence, this certification reinforces PCI's reputation as a technology-forward, compliance-first organization that leads with integrity, accountability, and innovation.' The HITRUST Assurance Program is the gold standard for data protection and information risk management. Its integrated, prescriptive, and scalable control framework allows organizations to address evolving cybersecurity challenges while aligning with leading standards such as ISO, NIST, HIPAA, PCI DSS, and COBIT. For PCI, the HITRUST recertification means: Clients can be assured that their data is being handled with the highest level of security, confidentiality, and regulatory adherence. Industry partners can rely on PCI's infrastructure as a secure extension of their own compliance ecosystems. Associates gain confidence and pride in working for a company that prioritizes cybersecurity, promotes continuous improvement, and invests in resilient systems and secure workflows. This achievement underscores PCI's unwavering focus on risk-based security management and regulatory alignment,' said Brian McGrath, Chief Information Officer of PCI. 'Our team has diligently woven compliance and security into the fabric of our culture, systems, and daily operations. The HITRUST r2 recertification reflects our dedication to operational excellence and our preparedness to protect sensitive data in a constantly evolving digital landscape. As PCI continues its national expansion with secure facilities in the Southeast, Northeast, Midwest, Southwest, West, and Mid-Atlantic regions, the HITRUST r2 Certification serves as a powerful differentiator, underscoring the company's position as a trusted partner for enterprise clients in healthcare, finance, insurance, government, and beyond. Recently, PCI also achieved ISO 9001 Certification, further validating the company's robust quality management systems and its dedication to continuous improvement, operational efficiency, and customer satisfaction across all business functions. To learn more about how PCI's HITRUST Risk-based, 2-year (r2) Certification can positively impact your mail operations, visit or contact a PCI Account Executive today. For more information about PCI and its initiatives, please email marketing@ About Postal Center International (PCI) Postal Center International (PCI) was founded in 1984 and is a leading mail, print, signs, fulfillment, promotional, packaging, and marketing solutions partner. Under the leadership of President & CEO Ismael Diaz since 2006, PCI has become renowned as one of the nation's fastest-growing postal and mail processing organizations and among the largest state-of-the-art printers. The company's family of brands employs more than 600 associates with locations in the Southeast, Southwest, Northeast, Midwest, West, and Mid-Atlantic regions, with a footprint totaling 562K square feet. PCI delivers exceptional solutions to enterprise clients in banking, financial, healthcare, insurance, hospitality, and government nationwide. PCI is a HIPAA-compliant Certified Minority Owned Diverse Supplier at the state and national levels. It holds multiple security, sustainability, and quality certifications, including HITRUST CSF®, ISO 9001, TruSight, FDR, PCI DSS, SOC 2 (Type 2), FSC, SFI, PEFC, and G7.
Yahoo
16 minutes ago
- Yahoo
CloudCover Receives Growth Investment from Argentum to Accelerate Global Expansion and Technology Innovation
IRVING, Calif., July 10, 2025 /PRNewswire/ -- CloudCover, a leading provider of third-party maintenance (TPM) and IT lifecycle management solutions powered by its cloud-based CoverIT™ platform, announced yesterday a growth investment from Argentum, a New York-based growth equity firm that partners with founder-led B2B software and technology-enabled services companies. The investment will support CloudCover's continued expansion into global markets and accelerate the development of its platform, CoverIT™—a purpose-built service operations platform that enables more efficient and scalable TPM delivery across the IT ecosystem. "CloudCover has reached a pivotal point in its growth journey," said Jeff Huggins, founder and CEO of CloudCover. "The opportunity to lead the TPM and IT lifecycle management markets through technology innovation is massive—and accelerating. Argentum is the right partner to help us scale, without compromising the culture, vision, or execution that got us here. We're incredibly proud of the team we've built and energized by the road ahead," Mr. Huggins will continue to lead the Company as Chairman and CEO and remain the majority shareholder after the investment. CloudCover's platform and services are used by major IT channel partners to deliver flexible, cost-effective infrastructure support and field services around the globe. The company's differentiated platform model and partner-first approach have fueled rapid growth in both North America and international markets. "We've earned the trust of some of the biggest names in the channel by delivering reliability, responsiveness, and the flexibility they need to win," said Robert Kenney, Chief Revenue Officer at CloudCover. "This partnership with Argentum allows us to invest further in our partner ecosystem, continue our international expansion, and deliver an even higher standard of support." "CloudCover's purpose-built platform coupled with its global service capabilities offers its channel partners the opportunity to participate in the lucrative TPM market in a frictionless way with limited investment and under their own brand. We believe this "channel-first" strategy represents a highly differentiated approach to the TPM market that positions CloudCover to continue its rapid growth, said Daniel Raynor, Managing Partner at Argentum. "We're excited to support CloudCover's experienced leadership team during the Company's next phase of growth and innovation." CloudCover joins a portfolio of founder-led companies backed by Argentum that are transforming their industries through innovation, customer focus, and operational excellence. About CloudCoverCloudCover is a leading provider of third-party maintenance (TPM) and IT lifecycle management solutions for the global IT channel. Powered by its purpose-built CoverIT™ platform, CloudCover enables partners to deliver efficient, flexible infrastructure support at scale. With a global footprint and a partner-first mindset, CloudCover is transforming how IT services are delivered and managed worldwide, from desktop to data center. Learn more at About ArgentumArgentum is a New York-based growth equity firm that helps scale bootstrapped, capital efficient B2B software, technology-enabled, and business services companies. The firm provides capital to accelerate growth, fund acquisitions, and generate shareholder liquidity. Over its 30+ year history, Argentum has invested in over 100 companies, supported more than 200 add-on acquisitions, and been named to Inc's list of Top Founder Friendly Investors for five consecutive years. Argentum fills the growing gap between venture capital funds and later stage PE firms by targeting capital-efficient companies that are not seeking a change in control. Learn more at View original content to download multimedia: SOURCE CloudCover IoT, Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
